By Momo Yamamoto, Senior Investor Research Analyst, LSN
One of the most valuable aspects of attending RESI Boston is the opportunity to hear directly from the investors and strategic partners actively funding and partnering with early-stage life science companies.
This year’s agenda features an outstanding lineup of leaders representing global pharmaceutical companies, venture capital firms, strategic investors, government funding organizations, and mission-driven investment groups. Their sessions will provide firsthand insights into today’s investment landscape, what they look for in emerging technologies, and how startups can position themselves for successful fundraising and partnership discussions.
Farnaz Bakhshi American Cancer Society BrightEdge
Alan Chiu Breakthrough T1D
Yvanka de Soysa Foreground Capital
Shane Duffy Avanos Medical
Nimisha Gupta Jazz Pharmaceuticals
Sam Gussman-Toh ARPA-H
Jonathan Illicki Industrifonden
Nikhil Mutyal AstraZeneca
Rohit Nuwal TELUS Ventures
Parthiban Rajasekaran Sanofi
Armin Rump Otsuka Pharmaceutical Co., Ltd
Register Today for RESI Boston 2026
Don’t miss your opportunity to learn directly from these industry leaders while connecting with hundreds of active investors, strategic partners, and innovative life science companies during Biotech Week Boston.
Join us September 22–23 in Boston, followed by three days of virtual partnering on September 25, 28, and 29.
Register now to secure your spot, take advantage of Early Bird savings, and begin scheduling meetings with the global life science investment community.
The U.S.-based research and business development arm of a global pharmaceutical company serves as its international innovation and partnering platform. Rather than operating as a traditional venture capital investor, the firm identifies and evaluates external innovation to strengthen the parent company’s research and development pipeline. The firm collaborates with biotechnology and pharmaceutical companies worldwide through strategic partnerships, in-licensing, co-development, and other business development transactions to accelerate the advancement of innovative medicines. The firm focuses on therapeutic innovation across anti-infectives, central nervous system disorders, oncology, autoimmune diseases, and metabolic diseases.
The firm is open to a broad range of therapeutic modalities and actively seeks novel drug candidates, platform technologies, and translational research programs that align with its strategic development priorities. The firm evaluates opportunities across preclinical and clinical development and pursues flexible partnership structures tailored to the needs of each program.
From a company and management team perspective, the firm seeks partners with differentiated science, strong intellectual property, and compelling preclinical or clinical data supporting global development potential. The firm values companies with well-defined development strategies and innovative assets that can address significant unmet medical needs. Through its global development, regulatory, manufacturing, and commercialization capabilities, the firm works closely with partners to advance promising therapies toward international markets.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
The firm is a healthcare-focused venture capital firm based in the United States that invests in novel, differentiated therapeutics addressing significant unmet medical needs. The firm makes direct equity investments across the full development spectrum, from preclinical programs through clinical- and commercial-stage companies. The firm participates in Seed and first institutional rounds, later-stage private financings, crossover rounds, and PIPE transactions, with the capacity to invest up to approximately $15M over the life of an investment. The firm can act as a lead, co-lead, or co-investor and invests in both private and public companies.
The firm focuses primarily on therapeutics in oncology, immunology, neurology, and rare diseases, while remaining open to other indications on a selective basis. The firm is stage-agnostic and prioritizes differentiated science, strong biological rationale, and programs with meaningful clinical and commercial potential. The firm seeks opportunities capable of addressing substantial unmet needs and reaching important development, regulatory, or commercial value-inflection milestones.
From a company and management team perspective, the firm prefers experienced leadership teams with strong scientific and drug development expertise. The firm partners closely with scientists, entrepreneurs, and institutional co-investors and provides strategic support through its pharmaceutical and healthcare industry network. The firm seeks to help portfolio companies advance toward clinical milestones, strategic partnerships, follow-on financings, and successful exits.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
The firm is a venture capital firm focused on supporting innovative healthcare companies across Asia, Australia, and North America. The firm invests in emerging life sciences businesses developing differentiated technologies and seeks opportunities with strong clinical and commercial potential. The firm takes a cross-border investment approach, helping portfolio companies access international capital, strategic partnerships, and global growth opportunities.
The firm invests across biopharmaceuticals, medical devices, and digital health, with a particular interest in novel therapeutics addressing significant unmet medical needs. Areas of interest include immuno-oncology, neuroscience, and other high-impact therapeutic innovations. The firm is open to companies at all stages of clinical development and evaluates opportunities based on the strength of the underlying science, clinical potential, and market opportunity.
From a company and management team perspective, the firm seeks innovative companies developing differentiated technologies with the potential to address meaningful unmet healthcare needs. The firm partners with management teams to support clinical development, commercialization, and international expansion, leveraging its cross-border network and experience in global healthcare investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
The firm is a venture capital firm founded by experienced biotechnology entrepreneurs and focused exclusively on novel therapeutics. The firm invests at the earliest stages of company development, from Seed through late preclinical programs, and typically supports portfolio companies through clinical proof-of-concept before pursuing strategic exit opportunities. The firm generally makes initial equity investments of approximately $3M–5M, with the capacity to invest up to $15M–20M per company over the life of an investment. Investments are primarily made through equity, although convertible structures may be used selectively. While the firm’s current portfolio has a strong European focus, it takes a globally opportunistic approach and is expanding its focus toward North American opportunities.
The firm invests exclusively in therapeutics and is both modality- and indication-agnostic. The firm prioritizes highly innovative drug candidates with differentiated mechanisms of action, compelling scientific rationale, and significant unmet medical need. Rather than focusing on specific therapeutic areas, the firm emphasizes development stage, scientific quality, and commercial potential. In addition to participating in financing syndicates, the firm is also active in company creation and the formation of new biotechnology ventures.
From a company and management team perspective, the firm values experienced founders and leadership teams but does not impose strict requirements. The investment team works closely with portfolio companies on R&D strategy, capital allocation, financing, and corporate development, leveraging longstanding relationships with academic researchers, entrepreneurs, and biotechnology investors to help companies reach critical value-inflection milestones. The firm is open to acting as either a lead investor or co-investor depending on the opportunity.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Nearly nine out of ten life science startups fail. Not because the science is poor, but because they never connect to the right capital and strategic partners. Solving that is the reason Life Science Nation exists, and for more than fifteen years our work has come down to one thing: finding parties who need each other and matching them.
As some readers know, LSN has been addressing this pervasive dilemma through the LSN Labs Anchor Node Program. An Anchor Node combines LSN’s commercialization methodology and global capital formation network with a regional partner’s laboratories, entrepreneurial programs, and operating platform to produce investment-ready life science companies.
As we expanded the Anchor Node Program across Boston, Australia, Japan, Korea, the UK, and Brazil, a clear pattern emerged: regional partners constantly brought their local VCs to the table seeking international capital. At the same time, our own data across five global RESI events revealed that twenty percent of all partnering meetings were already investor-to-investor.
So we decided to formalize it, and provide a dedicated room for these partners to connect.
The Cross-Border Investor Luncheon, CBIL, is a private luncheon at RESI Boston for regional and international investors seeking syndicate partners. Regional investors have access to exceptional companies that often never reach international investors. International investors have access and reach that regional funds cannot build alone. Both are looking for the same thing across Asia, Europe, North America, and South America.
Attendance is screened. CBIL is for active investors seeking syndicate partners outside their own region, whether that means bringing international capital into local deals or gaining access to deal flow in regions where they have no presence.
Taking place on Wednesday, September 23, CBIL follows the format of the Global Family Office BioForum luncheon (GFOB luncheon takes place on Tuesday, September 22), now in its eighth year. Across those eight years, GFOB has brought family offices together to find each other, form alliances, and build syndicates. CBIL is the natural next step, applying the same private, curated format to the international investor community.
“The future of life science investing is not just finding great companies. It is finding great syndicate partners in the global arena.”
The firm is an investment firm based in Europe that is developing a growth-focused investment strategy spanning life sciences and professional services. Founded by entrepreneurs with a successful track record of building and exiting a global technology company, the firm seeks to support innovation and long-term business growth through both early-stage venture investments and investments in established businesses. Within life sciences, the firm typically invests up to approximately €500K in Series A financings, with smaller investments at the Seed stage. The firm generally invests alongside other institutional investors through syndicated rounds.
The firm invests in life science and healthcare companies developing innovative, technology-enabled solutions. Its primary focus is on businesses with scalable, service-oriented or technology-driven business models. While the firm is open to early-stage opportunities, it favors companies that have demonstrated a viable business model and a clear pathway toward commercial scale.
From a company and management team perspective, the firm seeks founders with compelling value propositions that address meaningful unmet needs. The firm typically participates as a co-investor and provides value beyond capital through its entrepreneurial experience, deep industry expertise, and extensive professional network.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
